$STX

MOSLEY WILLIAM D sold $297K of STX

MOSLEY WILLIAM D (CEO) sold 320 shares of Seagate Technology Holdings plc (STX) at $926.83 ($0.30M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MOSLEY WILLIAM D
Published Jun 2, 2026, 9:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STX
Neutral
medium confidence
Mentioned
$STX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STXNeutralLow
01

Why it matters

Routine 10b5-1 insider sale disclosure; typically low informational content, but can slightly influence short-term sentiment or positioning.

02

Market read

A disclosed insider sale under a pre-arranged 10b5-1 plan; expected to be a low-impact event for trading decisions absent other catalysts.

03

What to watch

The filing does not indicate whether the CEO sold for diversification/tax purposes beyond the 10b5-1 structure, limiting interpretability.

Relevance 6/10Novelty 2/10Timing: Filed June 2 after the June 1 sale; potential same-day sentiment read-through.

Background

SEC Form 4 insider transaction disclosure for Seagate Technology Holdings plc (STX).

Company-level read

Ticker impact

$STXNeutralMedium confidence
Context

Seagate CEO William D. Mosley sold $296.6K of STX shares in an open-market transaction under a pre-arranged 10b5-1 plan on June 1.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief unless accompanied by other news.

Evidence & confidence

The filing is a routine insider transaction and explicitly states a pre-arranged 10b5-1 plan, which typically reduces signaling value.

Market effects

Minimal; this is company-specific insider activity with no sector-wide catalyst described.

None indicated.

None indicated.

Counterpoint

Because the sale is 10b5-1, it may not reflect bearish expectations; traders may ignore it unless there is unusual volume or repeated sales.

Key entities

  • Seagate Technology Holdings plc

    Subject of the Form 4 insider transaction disclosure.

  • William D. Mosley

    CEO and officer/director who sold 320 shares of STX.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVDAHighAI 9/10

Markets News, Aug. 27, 2026: Nvidia Stock Powers Higher After Earnings, Driving Tech Gains; Nasdaq Closes Sharply Higher

Nvidia (NVDA) reported strong Q2 earnings and raised Q3 revenue guidance to $108B, driving its stock up 9% and boosting tech sector gains. Nasdaq, S&P 500, and Dow closed higher. Other notable movers include Okta (OKTA) +29%, Salesforce (CRM) +23%, and CrowdStrike (CRWD) +20%. Corporate profits surged $400B in Q2, partly due to $71B in tariff refunds.

$STXMed

Moody’s upgrades Seagate Data rating on AI demand strength

Moody's upgraded Seagate Data's corporate family rating to Ba1 from Ba2, citing AI-driven demand for high-capacity HDDs. The agency expects revenues to grow over 30% annually, reaching $20B, and debt to EBITDA to fall below 0.5x. Seagate faces risks from revenue concentration and pricing pressures. The company had $1.7B in cash and access to a $1.3B credit facility as of July 2026.

$MRNAHighAI 8/10

3 Stocks Soared, 3 Stocks Slumped

Moderna (MRNA) surged 176.97% to $174.38 after reporting positive trial results for a cancer therapy with Merck (MRK). Estee Lauder (EL) rose 16% to $98.01 with revenue up 6.5% Y/Y. MicroStrategy (MSTR) gained 12.68% as Bitcoin prices rose. Nebius (NBIS) fell 10% after a $4.5B convertible note offering. Seagate (STX) dropped 8% to $832.56.

$STXMed

REG - Shield Therapeutics - Shield assumes full control of ACCRUFeR® in the US

Shield Therapeutics (STX) will take full control of ACCRUFeR® in the US from Viatris by September 30, 2026. The deal is expected to boost Shield's profitability and growth, with no upfront payments to Viatris. Shield will pay royalties on US net sales, ranging from high single digits to mid-teens over five years, and retain all gross profits from US sales. The transaction is anticipated to enhance Shield's financial profile and support its path to sustained profitability.